FLXN - Flexion Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
44,050
22,524
355
0
0
Cost of Revenue
6,852
7,336
4
-
-
Gross Profit
37,198
15,188
351
-
-
Operating Expenses
Research Development
59,984
53,079
51,231
41,314
32,691
Selling General and Administrative
128,701
121,311
78,801
28,466
13,372
Total Operating Expenses
188,685
174,390
130,032
69,780
46,063
Operating Income or Loss
-151,487
-159,202
-129,681
-69,780
-46,063
Interest Expense
15,752
15,712
11,268
1,747
571
Total Other Income/Expenses Net
1,005
688
-250
-1,887
-928
Income Before Tax
-162,240
-169,659
-137,481
-71,894
-46,315
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-162,240
-169,659
-137,481
-71,894
-46,315
Net Income
-162,240
-169,659
-137,481
-71,894
-46,315
Net Income available to common shareholders
-162,240
-169,659
-137,481
-71,894
-46,315
Reported EPS
Basic
-
-4.49
-4.16
-2.84
-2.15
Diluted
-
-4.49
-4.16
-2.84
-2.15
Weighted average shares outstanding
Basic
-
37,751
33,027
25,297
21,497
Diluted
-
37,751
33,027
25,297
21,497
EBITDA
-
-152,233
-129,681
-68,996
-45,506